Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00381862 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
A Phase 2 study of Colorectal Cancer and Nausea and Vomiting, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 6
- Study locations
NCT00381862: Completed Phase 2 study of Colorectal Cancer and Nausea and Vomiting, sponsored by OHSU Knight Cancer Institute.
NCT00381862 is a Phase 2 study of Colorectal Cancer and Nausea and Vomiting that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 54 participants, below the 1,545-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (97% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00381862, a Phase 2 study of Colorectal Cancer and Nausea and Vomiting, has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 6
- Study locations
Study Summary
RATIONALE: Aprepitant, palonosetron, and dexamethasone may help lessen or prevent nausea and vomiting in patients receiving chemotherapy. PURPOSE: This phase II trial is studying how well giving aprepitant together with palonosetron and dexamethasone works in preventing nausea and vomiting caused by chemotherapy in patients receiving chemotherapy for metastatic colorectal cancer.
Conditions Studied
Interventions
- DRUG dexamethasone
- DRUG fluorouracil
- DRUG leucovorin calcium
- DRUG irinotecan hydrochloride
- DRUG aprepitant
Study Locations (6)
Georgia
- St. Josephs/Cander Hospital - Savannah
Hawaii
- Kaiser Permanente - Hilo
Illinois
- Ingalls Memorial Hospital - Harvey
Missouri
- Kansas City Cancer Center - Kansas City
Oregon
- OHSU Knight Cancer Institute - Portland
Texas
- Texas A & M university / Scott and White Clinic - Temple
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2006-06 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
What the finished NCT00381862 record still lists
NCT00381862 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 1,545-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which dexamethasone is the first listed.
NCT00381862 lists 6 locations in 6 states (Georgia, Hawaii, Illinois).
Frequently Asked Questions
What is clinical trial NCT00381862 about?
NCT00381862 is a clinical study titled "Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX". RATIONALE: Aprepitant, palonosetron, and dexamethasone may help lessen or prevent nausea and vomiting in patients receiving chemotherapy. PURPOSE: This phase II trial is studying how well giving aprepitant together with palonosetron and dexamethasone works in preventing nausea and vomiting caused b...
What is the current status of trial NCT00381862?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2006-06. Estimated completion is 2008-07.
What conditions does trial NCT00381862 study?
This clinical trial studies the following conditions: Colorectal Cancer, Nausea and Vomiting.
What interventions are being tested in trial NCT00381862?
The interventions under investigation include: dexamethasone (DRUG), fluorouracil (DRUG), leucovorin calcium (DRUG), irinotecan hydrochloride (DRUG), aprepitant (DRUG).
Who is sponsoring clinical trial NCT00381862?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00381862 being conducted?
This trial has 6 study locations across Georgia, Hawaii, Illinois, Missouri, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00381862's enrollment target sits among peer trials
54 264th of 381 higher than 116 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
RECRUITING · Phase 2
-
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
RECRUITING · Phase 2
-
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia